Tech Company Financing Transactions
MyoKardia Funding Round
On 4/30/2015, MyoKardia received $46 million in Series B financing from Casdin Capital, Cormorant Asset Management and Perceptive Advisors.
Transaction Overview
Company Name
Announced On
4/30/2015
Transaction Type
Venture Equity
Amount
$46,000,000
Round
Series B
Proceeds Purpose
Proceeds from the financing will be used to advance and expand the company's portfolio of potential therapies for hypertrophic and dilated cardiomyopathies (HCM and DCM), including its lead drug candidate, MYK-461, which is currently in Phase 1 clinical trials.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1000 Sierra Point Pkwy.
Brisbane, CA 94005
USA
Brisbane, CA 94005
USA
Phone
Website
Email Address
Overview
MyoKardia is dedicated to revolutionizing the treatment of cardiovascular disease. The company's first programs include hypertrophic and dilated cardiomyopathy (HCM and DCM), which together afflict approximately 1 million people in the United States, and for which no novel therapeutics have been brought to market in over a decade.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tassos Gianakakos
Chief Financial Officer
Taylor Harris
Chief Medical Officer
Marc Semigran
Chief Scientific Officer
Robert McDowell
VP - Bus. Development
Jake Bauer
VP - Human Resources
Ingrid Boyes
Browse more venture capital transactions:
Prev: 4/30/2015: Circle venture capital transaction
Next: 4/30/2015: Earshot venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs